Vaccinia Capping System For mRNA Therapeutics

Reliable manufacturing materials are critical for the continued success and expansion of mRNA therapeutics. To support this growing need, the new Vaccinia Capping System offers a solution backed by ten years of manufacturing expertise, covering the pre-pandemic era through the height of global COVID-19 response. This system utilizes GMP Grade, Animal Origin Free (AOF) mRNA Guanylyltransferase and Methyltransferase to ensure strict compliance and minimize regulatory risk.

Designed for scalability, the system supports production needs ranging from initial R&D phases to full commercial manufacturing. By prioritizing robust supply chains, developers can enhance business continuity and gain better financial control over their projects. Manufacturers ready to integrate these enzymes into their development process can currently request pre-launch test samples for evaluation.